GSK: Licence to (K) Ill

Seroxat - 90% of injury claims seen by David Healy NOT caused by SSRI

2010-06-24T15:27:00.000-07:00

In over 90% of the SSRI cases on which I have been

approached, I have given the view that the injuries in question have
not been caused by the SSRI. I have charged nothing for the great
majority of these reports, or nothing for any reports I have offered to
coroners' courts for the purposes of inquests.

http://www.springerpub.com/journalsamples/contra_Pfizer.pdf

ETHICAL HUMAN PSYCHOLOGY & PSYCHIATRY: AN INTERNATIONAL JOURNAL OF

CRITICAL INQUIRY

Volume 7, Number 3, Fall/Winter 2005

CONTRA PFIZER

By David Healy

In July 2004, Pfizer posted an ad hominem attack on me. on the Food and

Drug Administration' (FDA) Web site under the heading of documents

relevant to a then forthcoming Psychopharmacologic Drugs Advisory

Committee (PDAC) hearing on the use of antidepressants in children

(Ryder, 2004). FDA refused to post my response to the issues raised in

the Pfizer document. This response has been adapted for a freestanding

publication,

and may be timely in light of the fact that the FDA has scheduled a

further hearing on treatment-induced suicidality in adults for the fall

of 2005. In completing this piece, I remain heavily constrained by

confidentiality orders, and it can be noted that Pfizer has attempted

to enforce such orders vigorously by means of court action.

Pfizer's letter starts with a commitment to open debate. The letter

then seeks to attack my credibility in an ad hominem way rather than to

address the scientific issues. This attack comes despite the fact that

I have been previously invited by Pfizer to chair symposia for them, to

author articles for journal supplements for them, to give international

guest lectures for them, and to adjudicate on studies submitted for

Pfizer research awards

for them. Clearly, at one point Pfizer thought me a credible scientist

in the area of psychopharmacology."

More recently, however, when scientists from Pfizer have sought to have

me come and speak at forums, they have been told by their superiors

that this is not appropriate. Of even greater interest is that the

senior Pfizer physician representing sertraline at the September

hearings, Dr. C. Kremer, when working for another company had been a

key person supportive of my involvement as an expert witness in court

actions involving fluoxetine.

It has in fact been very difficult to get issues of suicidality and

psychotropic drugs debated in academic forums. In one of the few such

forums, at an Irish College of Psychiatrists meeting in 2003, my

understanding is that many clinicians and academics in the audience

were briefed by individuals linked to Pfizer and GlaxoSmithKline on

issues to raise with Healy. Many of these issues are reproduced in this

letter from Pfizer.

At other scientific meetings to which I have been invited to contribute

on these issues, such as the International Society of

Pharmacoepidemiology annual meeting, distinguished academics with links

to some of the major companies producing selective serotonin reuptake

inhibitors (SSRIs), who have never heard me present the data, it would

appear, apparently

sought to have me removed from the scientific program. Yet, when later

given the chance to challenge the points I make, they have failed to

ask me any questions in public.

I believe this effort to close down debate has little to do with the

scientific issues, in that my work on these points has been extensively

peer-reviewed and published in six different journals. I have taken the

unusual step of presenting many of these reviews, especially the

negative ones, on the Internet to make it clear where others differ in

their interpretations

of the data (Healy, 2004). I believe the issue has much more to do with

my temerity in being prepared to testify as an expert for plaintiffs.

Since my involvement as an expert witness, I have received documents

from at least one public relations company working for one of the

relevant SSRI companies that have listed me as a problem to be managed,

and I think what we are witnessing here is part of the management

strategy.

Before proceeding, it is worth putting the issue of expert witnessing

in context. In over 90% of the SSRI cases on which I have been

approached, I have given the view that the injuries in question have

not been caused by the SSRI. I have charged nothing for the great

majority of these reports, or nothing for any reports I have offered to

coroners' courts for the purposes of inquests.

Moreover, regarding actions by plaintiffs in general, far from being

plaintiff friendly, I have been used as an expert by the National

Health Service in the United Kingdom, and in that capacity have offered

reports favoring the defense rather than plaintiffs in, again, over 90%

of cases.

It should also be noted that I have no interests in any competing

treatments. I use antidepressants, including SSRIs, to treat both

adults and children, and, as a former secretary of the British

Association for Psychopharmacology, convened a consensus conference and

authored the ensuing guidelines on the issue of treating children with

psychotropic drugs (BAP, 1997). These guidelines endorsed the cautious

use of such drugs, a position I maintain to this day.

SPECIFIC RESPONSES TO PFIZER

In its July 2004 letter to the FDA, Pfizer made 12 points to which I

will respond.

First

First, the company claims its depression program has shown no evidence

of suicidality. In fact, Pfizer's depression program has a roughly

50% failure to demonstrate efficacy in clinical trials, and many of the

trials undertaken with Zoloft remain unpublished. So poor were the

results from the early trials that they raised concerns that this drug

might not get approved, as publicly available memoranda from Dr. P.

Leber to Dr. R. Temple indicate (Leber, 1991a, 1991b).

Zoloft, however, on the back of a selected set of published-only

studies, has been sold by Pfizer as an SSRI with unparalleled evidence

of efficacy. Arguably, there is a comparable discrepancy between the

claims made by Pfizer and the evidence base for those claims, and the

claims made for the use of Paxil for minors and the evidence base for

that use. The claims in the latter instance were characterized in June

2004 by the attorney general from

New York, Elliot Spitzer, as close to fraudulent. Regarding the

evidence for suicidality from the Zoloft studies, in over 20 cases

investigators have concluded that Zoloft has caused

suicidality/suicidal acts, and in more than 20 further cases, Pfizer

monitors overrode the judgments of the clinical investigators who had

not linked Zoloft to suicidality. These Pfizer personnel attributed

causality to Zoloft in the cases of these suicidality/suicidal events.

Given this, it is something of a mystery as to how Pfizer can claim

there is no evidence their drug causes suicide.

When data from the studies undertaken and submitted to FDA are analyzed

statistically, the point estimate for the odds ratio of suicidal acts

on Zoloft compared to placebo is greater than 1.0, which is indicative

of a risk, and probably greater than 2.0. Pfizer has sought to manage

this problem by a variety of methods, detailed below. The question of

what a point estimate greater than 1.0 means in the context of SSRIs

and suicide raises issues of interpretation that epidemiologists and

others interested in safety issues have to deal with. Many reputable

figures in these areas, including some working in the FDA, would argue

that the correct interpretation of a point estimate greater than 1.0 is

that given that this hazard is a potentially lethal one, it deserves

appropriate warnings and monitoring. ...cut....

Overarching Issues

The current crisis with SSRI agents has profound philosophical and

methodological underpinnings that deserve better than ad hominem

attacks. Current procedures to manage the entry of drugs onto the

market favor the detection of drug effects and are biased against the

detection of adverse effects. For instance, in order for a drug to be

licensed it has to show superiority to placebo in two controlled

trials. Companies, however, can run ten or more trials in carefully

selected samples using instruments carefully designed to pick up any

effect in order to demonstrate this, and even if the results show the

drug failing to beat placebo in the clear majority of trials, this is

not held against them. These other trials are commonly termed failed

trials rather than drug failures. This was a live issue in the

licensing

of Zoloft as the Leber memoranda outlined above make clear.

In contrast, the demonstration of a safety issue is not handled in this

way. In the case of safety, regulators only act if the overwhelming

preponderance of the data show a hazard. These differences in approach

have at their heart unresolved philosophical issues about the nature of

statistics. Safety data are typically presented in terms of confidence

intervals, so that, for instance, in recent antidepressant studies, the

rate of suicides on drugs compared to placebo is typically of the order

of two times greater but what is termed the confidence interval

surrounding this figure of 2.0 might be anything from .9 to 4.4.

There are two ways to interpret such a finding. First, according to a

school of thought stemming from R. A. Fisher, is the view that nothing

has, in fact, been shown unless the confidence interval does not

include 1.0-for instance, only a confidence interval that shows a

range from 1.1 to 4.4 for instance would be significant. Pfizer is

relying heavily on just this point to claim that it has not been proven

that Zoloft causes suicidal acts.

However, the Neymann-Pearson school of thought, and, in fact, the whole

point behind confidence intervals, argues that the best estimate of the

effect is 2.0, in this case, and that with a confidence interval of .9

to 4.4, while the data may be consistent with no effect, the scientific

data are also consistent with a 4.4-times increase in risk. The 2.0

figure is the one regarding which we can be most confident and is the

one that should dictate whether, for instance, warnings are placed on a

treatment.

FAIR USE NOTICE: The material is made available for educational

purposes, to advance understanding of human rights, democracy,

scientific, moral, ethical, and social justice issues, etc. It is

believed that this constitutes a 'fair use' of any such copyrighted

material as provided for in Title 17 U.S.C. section 107 of the US

Copyright Law. This material is distributed without profit.

Seroxat - Panorama not always noted for its accuracy says Lord Winston

2010-06-24T08:58:00.000-07:00

Lord Winston My Lords, I declare an interest as the director of research and development at Hammersmith Hospitals NHS Trust. Does the Minister not agree that Seroxat and the class of drugs that deal with serotonin in the brain are the most effective anti-depressants that we currently know? Seroxat has been in use for more than 12 years and is available in more than 100 countries where none of the side effects mentioned has been highlighted. The "Panorama" programme has not always been noted for its accuracy in other areas. It would be premature to condemn what is an extremely good drug. The side effects reported are those commonly reported in recovering depressive patients who are not taking the drug.

http://hansard.millbanksystems.com/lords/2003/may/15/drug-side-effects-reporting-system

Seroxat - BBC Panorama analysis of e-mails by Charles Medawar

2010-03-31T12:25:00.001-07:00

Seroxat - BBC Panorama analysis of e-mails by Charles Medawar

Paroxetine, Panorama and user reporting of
ADRs: Consumer intelligence matters in
clinical practice and post-marketing drug surveillance

http://www.socialaudit.org.uk/IJRSM-161-169.pdf

Charles Medawar a,∗, Andrew Herxheimer b, Andrew Bell c and Shelley Jofre c

a Social Audit Ltd., London, UK bDIPEx Project, Department of Primary Health Care, University of Oxford, Oxford, UKc British Broadcasting Corporation (BBC), London, UK

1. Introduction
An estimated 4.4m people recently watched “Secrets of Seroxat” (Panorama, BBC-TV), a 50-minute
programme about paroxetine, an SSRI antidepressant for which UK general practitioners wrote an estimated 4.7m prescriptions in 2001.

2. Methods
Printouts of the 1,374 Panorama emails (less duplicates) were closely read, and categorized as positive
(234 reports [17%] rated from very positive to “worth taking – just”), negative (647 [48%], rated from
not worth taking to severely disabling), and uncertain (469 [35%], giving no or insufficient evidence
of paroxetine use).

Most Seroxat clients dropped because they were taking other drugs in conjunction with their paroxetine

2009-12-11T09:41:00.000-08:00

SEROXAT SUFFERERS - STAND UP AND BE COUNTED: Most Seroxat clients dropped because they were taking other drugs in conjunction with their paroxetine

The reason why there are only 600 or so claimaints left in the UK Seroxat class action against GSK is because many cases were dropped because of doctors prescribing other drugs in conjunction with Seroxat. I know personally of many people who have been dropped from the class action because of this and other factors...

Oh and by the way, Janice Simmons of the seroxatusersgroup met with UK prime minister Gordon Brown at downing street a few days ago. Bear in mind that there is currently a 4 year long investigation into the conduct of GSK regarding Seroxat prescribing to children/suppression of negative clinical data etc..

http://fiddaman.blogspot.com/2007/11/honourable-members.html

But bear in mind also that JP Garnier( GSK CEO) is also on "Gordon Browns Business Council"...
Also worthy of thought is what GSK means to the UK economy..
It is virtually an English institution with its roots firmly cemented in UK research/developement/sponsorship/employment etc..
It is the UK's Major Pharma Cash Cow..
And it is prized very much as being such...

Will be interesting when more info on this meeting begins to bear fruit...
But i have a feeling that the UK seroxat scandal is a can of worms which has been eating its way right through the core of UK politics for quite some time now...
And when something has become that rotten..
Most people won't touch it...

Posted by truthman30 at December 2, 2007 04:24 PM

http://209.85.229.132/search?q=cache:17IP6JGo25kJ:www.furiousseasons.com/movabletype/mt-comments.cgi%3Fentry_id%3D1151+seroxat+group+litigation&cd=10&hl=en&ct=clnk
Posted by FID at 10:00

SEROXAT SUFFERERS - STAND UP AND BE COUNTED: So seven weeks after starting cold turkey Bob Fiddaman goes to The Robin 2 - The Midlands Premier 700 capacity live concert venue !!

2009-12-02T01:54:00.000-08:00

SEROXAT SUFFERERS - STAND UP AND BE COUNTED: So seven weeks after starting cold turkey Bob Fiddaman goes to The Robin 2 - The Midlands Premier 700 capacity live concert venue !!

Withdrawal from paroxetine can be severe, warns FDA -- Tonks 324 (7332): 260 -- BMJ

2009-11-29T09:08:00.000-08:00

Withdrawal from paroxetine can be severe, warns FDA -- Tonks 324 (7332): 260 -- BMJ

Alison Tonks, Bristol The first 150 words of the full text of this article appear below.

http://www.bmj.com/cgi/content/extract/324/7332/260

GlaxoSmithKline, a leading drugs manufacturer, was last week forced to admit that paroxetine, a widely prescribed antidepressant and the company's best selling drug, can cause severe withdrawal symptoms when stopped.

The Food and Drug Administration in the United States published a new product warning about the drug, and in the same week the International Federation of Pharmaceutical Manufacturers Associations declared the company guilty of misleading the public about paroxetine on US television a year ago.

"This drug has been promoted for years as safe and easy to discontinue," said Charles Medawar, head of Social Audit, a consumer research group specialising in medicines policy. "The fact that it can cause intolerable withdrawal symptoms of the kind that could lead to dependence is enormously important to patients, doctors, investors, and the company.

"GlaxoSmithKline has evaded the issue since

SEROXAT SUFFERERS - STAND UP AND BE COUNTED: *** Exclusive - what it was really like for Fiddaman during cold turkey from Seroxat - here we bring you day 8

2009-11-29T08:37:00.000-08:00

SEROXAT SUFFERERS - STAND UP AND BE COUNTED: *** Exclusive - what it was really like for Fiddaman during cold turkey from Seroxat - here we bring you day 8

SEROXAT SUFFERERS - STAND UP AND BE COUNTED: Day 8 and Fiddaman is clearly finding it a laugh !!

2009-11-29T06:48:00.000-08:00

SEROXAT SUFFERERS - STAND UP AND BE COUNTED: Day 8 and Fiddaman is clearly finding it a laugh !!: "Day 8 and Fiddaman is clearly finding it a laugh !!
click on link below to personally verify this Bob Fiddaman Blogspot Exclusive ***"

Did West Mids Police Advise MH Drug Blogger On Blog Tactics ?

2009-11-11T01:06:00.001-08:00

He said J Bryce is a GSK quisling - we say Mark Harvey of Hugh James is a liar

2009-11-10T00:44:00.000-08:00

SEROXAT SUFFERERS - STAND UP AND BE COUNTED: He said J Bryce is a GSK quisling - we say Mark Harvey of Hugh James is a liar

GSK to appeal Kilker case - statement

2009-10-14T00:54:00.000-07:00

GSK Statement on Jury Verdict in Paxil Product Liability Trial in Philadelphia Court of Common Pleas

http://bobfiddaman.blogspot.com/2009/10/gsk-to-appeal-kilker-case-statement.html

On October 13, 2009, a jury in the Philadelphia Court of Common Pleas returned a verdict against GlaxoSmithKline in a case alleging that Lyam Kilker was born with a rare heart defect as a result of his mothers use of Paxil during pregnancy.

GlaxoSmithKline disagrees with the verdict and will appeal. While we sympathize with Lyam Kilker and his family, the scientific evidence does not establish that exposure to Paxil during pregnancy caused his condition. Very unfortunately, birth defects occur in three to five percent of all live births, whether or not the mother was taking medication during pregnancy.

GlaxoSmithKline acted properly and responsibly in conducting its clinical trial program for Paxil, including sharing documentation and submitting results from studies on Paxil to regulators. Once approved for use, the company acted properly in marketing the medicine, including monitoring its safety, updating pregnancy information in the medicines labeling as new information became available, and in communicating important safety information to regulatory agencies, the scientific community and the public.

US Media enquiries:
Nancy Pekarek
(919) 483 2839
Mary Anne Rhyn
(919) 483 2839
Kevin Colgan
(919) 483 2839
Sarah Alspach
(919) 483 2839

Paxil Seroxat (birth defect) trial due to start today - "settled out of court last week"

2009-10-13T07:56:00.000-07:00

Paxil Seroxat (birth defect) trial due to start today - "settled out of court last week"

Paxil (birth defect) trial due to start today - "settled out of court last week"
http://bobfiddaman.blogspot.com/2009/10/paxil-seroxat-birth-defect-trial-due-to.html

http://www.network54.com/Forum/281849/message/1255423909/Paxil+%28birth+defect%29+trial+due+to+start+today+-+%26quot%3Bsettled+out+of+court+last+week%26quot%3B

--------------------------------------------------------------------------------

A second Paxil case, expected to begin next Tuesday, was settled out of court last weekend. The next is not scheduled to begin in mid-November.

source - full report read on -

http://thestar.blogs.com/ethics/2009/10/first-paxil-trial-goes-to-the-jury.html

date - October 09, 2009

Seroxat - My Violent Obsession (Boost Records)

2009-10-07T23:37:00.001-07:00

Artist: Seroxat

http://bobfiddaman.blogspot.com/2009/10/seroxat-my-violent-obsession-boost.html

Title: My Violent Obsession

Label: Boost Records

Format: CD

Release: October/2009

Catalog: BRCD01

Track list:

1.Endless Stream

2.Goddamn Noize

3.Panic Attack

4.Breathe In

5.Feels Like

6.Inside My Head

7.More I Know

8.Cryptomnesia

9.Wishes

Boost Records is proud to present Seroxat long awaited album "My violent obbsession"!

Five years since the debut album "Brutal Beats" has been released,and now Seroxat is surprising us

again with a new masterpiece.

9 Artistic tracks that range from psychedelic trance music

to heavy metal guitar riffs , Break beat to classical music And top notch vocals.

Some of the highlights in this masterpiece includes the hit "Panic Attack" which has already

been tested on dance floors all over the world.

"Breathe In" Which combines Psytrance with Opera and classical music.

"Feels like",a pure psychedelic break beat track with a bad ass rhythm!

"Wishes", the closing track of the album is a brilliant down tempo tune ,combining talented piano playing

along angelic voices and raw guitars, which sounds genius all together .

These are only a few of the tracks featured on this amazing new album.

Seroxat's new album is showing us that he matured through the years into a very talented artist who knows how to make smart music and uses many different genres and styles.

This is a must album to everyone who appreciates high quality,well produced sounds , and genuine music .

The album will be for available sale at http://www.beatspace.com

Seroxat sales "AVALANCHE" - so how did patients withdraw?

2009-09-01T03:15:00.000-07:00

FOI 09/309 - MHRA have NOT received David Healy Withdrawal Protocol **Updated

2009-08-27T08:52:00.001-07:00

FOI 09/309 - MHRA have NOT received David Healy Withdrawal Protocol **Updated
From: Fawbert, Stephen Date: 21/08/2009 11:25:53 To: Jeremy Bryce Cc: Gregor, Simon Subject: FOI 09/309 - Healy Withdrawal ProtocolDear Mr BryceThank you for your email of 17 August to Simon Gregor which has been passed to me as Freedom of Information Act Coordinator for VRMM Division.We have not received a revised withdrawal protocol dating from end of June or early July from Professor Healy.As stated in previous correspondence the Summary of Product Characteristics, which is produced by the marketing authorisation holder and approved by the MHRA does not include information about the effects of venlafaxine on serotonin and noradrenaline at different doses. Guidance from the National Institute of Clinical Excellence (NICE) on the treatment of depression states that 'At the standard dose of 75mg, venlafaxine is an SSRI. At doses of 150mg/day and above it also inhibits the reuptake of noradrenaline and, to a lesser extent dopamine. I hope this information is helpful.Yours sincerely Stephen FawbertStephen FawbertInformation for Public Health Group Vigilance and Risk Management of Medicines (VRMM)Medicines and Healthcare products Regulatory Agency (MHRA)Market Towers 14-1101, Nine Elms LaneLondonSW8 5NQTel: 020 7084 2788www.yellowcard.gov.ukwww.mhra.gov.

Seroxat/Paxil : Deception As A Marketing Tool - listen to how a corrupt BBC fixed it for Mark Harvey

2009-08-24T12:21:00.000-07:00

2.30 in Jofre says - " read a little bit in news paper about patients complaints" year 2000 about " Seroxat difficult to withdraw from" .. Jofre found it intriguing Jofre had only just started working on Panorama at that stage3.30 in " Jofre calls SSRI's "SELECTIVE Serotonin Reuptake Inhibitors"4.14 Jofre knew little of how the pharmcutical industry worked4 .30 in Ed says - lets look at antidepressant story4 45 Jofre says although problems with whole class of antidepressants we (bbc) decided to concentrate on SeroxatWhy we narrowed down on Seroxat1 because it was made by GSK2 all the drugs in class cause suicidal thinking on dose change3 Seroxat had a unique problem of withdrawal BECAUSE IT WAS LONGER ACTING ... we decided to focus research into this drug 6.00 in - 40 min Panorama film took Shelley Jofre 8 months to make6.10 in - It's not something you do lightly WE WERE TAKING ON the worlds second largest drug company7.30 We were talking to the lawyer the whole way through production9.30 in - Jofre says "we took a punt" on Dr David Healy

http://coventryuniversity.podbean.com/2007/11/01/one-woman-a-multinational-and-a-victory-shelley-jofre-panorama/

Tuesday1st Correspondence with the MHRA - interesting new blog

2009-07-09T14:27:00.001-07:00

http://tuesday1st-mhra-ppes-correspondence.blogspot.com/

The withdrawal hell of Seroxat doesn't look like much when reading about it - says Bangkok Bob Fiddaman

2009-07-07T13:44:00.001-07:00

The clouds had parted and for the first time in six years I felt like Bob Fiddaman again. The withdrawal hell of Seroxat doesn't look like much when reading about ithttp://209.85.229.132/search?q=cache:F7TcQYTp02AJ:www.scribd.com/doc/8240116/Interview-With-SeroxatPaxil-Campaigner+fiddaman+liquid+seroxat&cd=5&hl=en&ct=clnk

Seroxat / Paxil - UK a minimum of 25000 people withdraw annually without any help from a clinic - what is BOB FIDDAMAN'S problem?

2009-05-13T01:17:00.001-07:00

Total annual Seroxat sales year ending 2001 = 3.787 million

Total annual Seroxat sales year ending 2008 = 1.690 million

Reduction = 2.097 million

Intervals = 7

Average year on year reduction 2001/08 = 300,000

Max number of scripts per person per year NHS = 12

therefore (min) 25,000 less people per year take Seroxat

Benzodiazapine litigation - 13,000 legal aid certificates issued but only 1500 cases in court - see a pattern here?

2009-05-11T03:30:00.000-07:00

Medicines, Medical Devices and the Law - Google Book Search

http://books.google.com/books?id=0o4Dz2bK8oMC&pg=PA234&lpg=PA234&dq=myodil+legal+aid+uk&source=bl&ots=Wc3Scc651C&sig=A1UW_c9AvX1ph-gRZClgLgPC0dk&hl=en&ei=O_sHSsnuGc_LjAeNpqzlBA&sa=X&oi=book_result&ct=result&resnum=1

Myodil & Seroxat - Glaxo Laboratories Limited paid out, on average, £16,000 - see a pattern here?

2009-05-11T03:02:00.000-07:00

SEROXAT SUFFERERS - STAND UP AND BE COUNTED: Myodil & Seroxat: "Myodil & Seroxat

The Truthman has an excellent post over at GSK Licence to [K]ill

He writes:

The Scandalous story of Glaxo’s “Myodil” is eerily similar to the “Seroxat” Scandal…

Thousands of people harmed and maimed by a toxic GSK chemical..

Decades of denial ..

Then finally the truth emerges…

Notice a pattern of behavior here ?.."

SEROXAT SUFFERERS - STAND UP AND BE COUNTED: Myodil & Seroxat

2009-05-11T02:51:00.000-07:00

PAXIL ADDICTION - THE TRUTH - Paxil/Seroxat accounts for only 6.5% of English sales - see Tuesday1st blogspot

2009-05-11T01:53:00.000-07:00

SEROXAT SUFFERERS - STAND UP AND BE COUNTED: PAXIL ADDICTION - THE TRUTH - Paxil/Seroxat accounts for only 6.5% of English sales - see Tuesday1st blogspot:

"PAXIL ADDICTION - THE TRUTH -

Paxil/Seroxat accounts for only 6.5% of English sales - see Tuesday1st blogspot

truth here - http://tuesday1st.blogspot.com/2009/05/doh-1998-2008-england-ssri-snri-totals.html

uksurvivors : Message: Shelley Joffre / Panorama made biased & misleading documentaries

2009-04-20T02:45:00.000-07:00

uksurvivors : Message: Shelley Joffre / Panorama made biased & misleading documentaries: "The McKies enjoyed great media support, particularly from a BBC Team, headed by Shelley
Joffre. Working with the McKies, Ms. Joffre and her colleagues produced four Documentaries,
two by Frontline Scotland and two by Panorama. Each of the Documentaries was biased,
grossly misleading and involved editorial decisions not to report the Expert Findings of Mr.
Swann. Ms. McKie also has extensive support within the Scottish Parliament and names over
40 MSPs who are protecting her interests

http://www.shirleymckie.com/documents/SwannLettter28.4.05_001.pdf"

Fiddy said "getting better because I was tapering" & "I was happy in myself that I was 'getting there'."

2009-04-20T00:55:00.000-07:00

http://groups.yahoo.com/group/uksurvivors/message/43627

"I moved out of the marital home, leaving my 3 sons behind me. Again, I felt no emotion. I moved across the city to live with my sister. She educated herself on withdrawal problems and made things really comfortable for me. I owe her a great debt. I lived with her and her two children for about 5 months before being given keys to a one bedroom council flat just around the corner from her. In fact, part of the reason I was able to live so close to her was because the Housing Department had agreed that I needed someone close by to help me through withdrawal. I guess I have GSK to thank for my one bedroom council flat.

I was elated when I got my own place, it meant I could see my children again, more importantly show them how their dad was getting better because I was tapering - and had been during my time spent living with my sister.

The zaps were still with me as was the irregular sleep patterns but I was happy in myself that I was 'getting there'."

http://209.85.229.132/search?q=cache:8nuBzNWhEOcJ:www.whale.to/a/risks_outweigh_the_benefits.html+seroxat+litigation&cd=117&hl=en&ct=clnk&gl=ie
Posted by Fiddy at 19:54

"Janice said the group represents over 10,000 people all of whom have suffered adverse effects/withdrawal symptoms of Seroxat.

2009-04-20T00:46:00.000-07:00

"Janice said the group represents over 10,000 people all of whom have suffered adverse effects/withdrawal symptoms of Seroxat. She said her husband John had been on Seroxat since 19 ......."

Source - http://www.seroxatusergroup.org.UK/EMEA%20minutes%20April%202004.pdf

Meeting with EMEA on Monday 19th April 2004 at 11.00a.m. Until 1.00p.m.

7 Westferry Circus

Canary Wharf

London E14 4HB

Meeting arranged by Janice Simmons of www.seroxatusergroup.org.UK.

The European Agency for the Evaluation of Medicinal Products (EMEA) is a decentralised body of the European Union. Its headquarters have been in London since 1995.

http://www.emea.eu.int/htms/aboutus/emeaoverview.htm

BBC video footage of Seroxat charity swindler Andrew Isaacs from Neath Wales. - claiming SUG has 6500 members

2009-04-19T03:06:00.000-07:00

BBC video footage of the other Seroxat charity swindler Andrew Isaacs from Neath Wales. - claiming 6500 members

http://news.bbc.co.uk:80/media/video/39429000/rm/_39429732_seroxat_disco_vi.ram

http://news.bbc.co.uk/media/video/39429000/rm/_39429732_seroxat_disco_vi.ram